Get the Stockscreener App
0.9199
16.81%
0.1324
Oncolytics Biotech Inc stock is traded at $0.9199, with a volume of 1.54M.
It is up +16.81% in the last 24 hours and up +165.10% over the past month.
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer among others.
See More
Previous Close:
$0.7875
Open:
$0.8
24h Volume:
1.54M
Relative Volume:
2.42
Market Cap:
$37.93M
Revenue:
-
Net Income/Loss:
$-20.31M
P/E Ratio:
-3.4779
EPS:
-0.2645
Net Cash Flow:
$-21.07M
1W Performance:
+27.76%
1M Performance:
+165.10%
6M Performance:
-4.17%
1Y Performance:
-8.92%
1-Day Range:
$0.77
$0.9648
1-Week Range:
$0.71
$0.9648
52-Week Range:
$0.3258
$1.53
Oncolytics Biotech Inc Stock (ONCY) Company Profile
Compare ONCY with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ONCY
Oncolytics Biotech Inc
|
0.9199 | 37.93M | 0 | -20.31M | -21.07M | -0.2645 |
|
VRTX
Vertex Pharmaceuticals Inc
|
459.62 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.36 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
331.91 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
543.48 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
245.49 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Oncolytics Biotech Inc Stock (ONCY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-06-22 | Initiated | Maxim Group | Buy |
| Feb-17-21 | Initiated | H.C. Wainwright | Buy |
Oncolytics Biotech Inc Stock (ONCY) Latest News
Cancer Rates Are Surging in Young Adults -- Here's Where the Smart Money Is Going - PR Newswire
Oncolytics names Jared Kelly as CEO - MSN
Oncolytics Biotech stock takes off after naming new CEO - MSN
Big Cuts to U.S. Cancer Research May Create Historic Opening for Biotech Investors - Baystreet.ca
As Public Cancer Funding Wavers, Oncology's Brightest Breakthroughs Are Coming From Industry - PR Newswire
After Major Oncology Conference, All Eyes Turn to Industry Innovation - PR Newswire
Oncolytics (ONCY) Names Jared Kelly as New CEO and Board Member - GuruFocus
Oncolytics Biotech® Names New CEO to Accelerate Momentum in Immu - GuruFocus
Global Billion Dollar Oncology Industry Experiencing Substantial Growth Driven by Increasing Cancer Incidences - GlobeNewswire
Oncolytics Biotech stock takes off after naming new CEO | 2025-06-11 | Investing News - Stockhouse
Oncolytics Biotech Inc. - Baystreet.ca
Stocks In Play: Oncolytics Biotech Inc. - Barchart.com
Stocks In Play: Oncolytics Biotech Inc By Baystreet.ca - Investing.com Canada
Oncolytics Biotech (ONCY) Appoints New CEO, Jared Kelly - GuruFocus
Oncolytics Biotech Inc - Baystreet.ca
Stocks In Play: Oncolytics Biotech Inc - Barchart.com
Oncolytics Biotech Appoints New CEO to Drive Immunotherapy Advancements - TipRanks
Oncolytics Biotech® Names New CEO to Accelerate Momentum in Immunotherapy Programs | ONCY Stock News - GuruFocus
Oncolytics Biotech Taps $2B J&J Deal Architect as CEO, Accelerating Fast Track Cancer Programs - Stock Titan
(ONC) Investment Performance Report (ONC:CA) - news.stocktradersdaily.com
(ONC) Long Term Investment Analysis (ONC:CA) - news.stocktradersdaily.com
Oncolytics Biotech(R) to Present at the H.C. Wainwright 21st Annual Global Investment Conference - ACCESS Newswire
(ONC) Technical Patterns and Signals (ONC:CA) - news.stocktradersdaily.com
Exelixis Stock Surges 28% YTD: Should You Buy Now or Sell? - The Globe and Mail
(ONC) Market Dynamics and Trading Signals (ONC:CA) - news.stocktradersdaily.com
(ONC) Proactive Strategies (ONC:CA) - news.stocktradersdaily.com
Against the rise of early onset cancer: a Mugglehead roundup - Mugglehead Magazine
Why E2open Shares Are Trading Higher By 25%; Here Are 20 Stocks Moving Premarket - Benzinga
(ONC) Advanced Equity Analysis (ONC:CA) - news.stocktradersdaily.com
HC Wainwright Has Pessimistic Outlook of TSE:ONC Q2 Earnings - Defense World
Stocks In Play - Baystreet.ca
Q2 EPS Forecast for Oncolytics Biotech Reduced by Analyst - Defense World
Stocks in play: Oncolytics Biotech® Inc. - The Globe and Mail
Investor Attention Turns to Biotech as Traditional Cancer Research Models Strain - Baystreet.ca
Dow slumps 460 points, or 1.1%, in early trading following Trump's latest tariff threats targeting Europe and Apple - The Globe and Mail
New Data and Deal Flow Signal a Turning Point for Precision-Driven Cancer Biotechs - marketscreener.com
Oncolytics Biotech Inc. to Present New Clinical Trial Data at ASCO Showing Pelareorep's Unique Immune Activation Capabilities - marketscreener.com
Oncolytics (ONCY) Unveils Promising Phase I/II Clinical Trial Da - GuruFocus
Oncolytics Biotech Unveils Promising Pelareorep Data at ASCO 2025 - TipRanks
Oncolytics Biotech® to Present New Clinical Trial Data at ASCO Showing Pelareorep's Unique Immune Activation Capabilities | ONCY Stock News - GuruFocus
Oncolytics Brief: Presenting New Clinical Trial Data at ASCO Showing Pelareorep's Unique Immune Activation Capabilities - marketscreener.com
Oncolytics Biotech® to Present New Clinical Trial Data at ASCO Showing Pelareorep's Unique Immune Activation Capabilities - PR Newswire
HC Wainwright Issues Negative Outlook for TSE:ONC Earnings - Defense World
Oncolytics Biotech (NASDAQ:ONCY) Earns “Buy” Rating from HC Wainwright - Defense World
(ONC) Strategic Market Analysis (ONC:CA) - news.stocktradersdaily.com
ONCY: Analyst Reiterates Buy Rating with $5.00 Price Target | ONCY Stock News - GuruFocus
Analysts Set Oncolytics Biotech Inc. (NASDAQ:ONCY) Price Target at $4.33 - Defense World
Oncolytic Virus Therapy Market Detailed In New Research Report - openPR.com
Jones Trading Reaffirms “Hold” Rating for Oncolytics Biotech (NASDAQ:ONCY) - Defense World
Options Volatility and Implied Earnings Moves Today, May 16, 2025 - The Globe and Mail
(ONC) Market Performance Analysis (ONC:CA) - news.stocktradersdaily.com
Oncolytics Biotech Inc Stock (ONCY) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.68%
0.50%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):